The Statement

Building Africa’s Health Sovereignty From The Ground Up

A subsidiary of Microhaem Scientifics,
VAi is quietly rewriting what it means for Uganda — and Africa — to be truly prepared.

When the COVID-19 pandemic swept across the globe, it did not treat every country equally. Nations that had invested in local manufacturing capacity, robust supply chains, and sovereign health infrastructure fared measurably better than those who had outsourced those capabilities to international markets. Uganda, like much of sub-Saharan Africa, found itself dependent on supply lines that broke precisely when they were needed most. Vaccines sat in warehouses on other continents while communities waited. The lesson was not lost.

It was from that crucible that the Vaccine Access Initiative — VAi — was born. Formed through a deliberate collaboration between Uganda’s Ministry of Health, Microhaem Scientifics (MHS), and Imagine Pharmaceuticals, VAi entered the world not as a charity response or a temporary fix, but as a structural answer to a structural problem. The founding conviction was straightforward: a nation that cannot access, manage, or manufacture its own health technologies is not fully sovereign — and the consequences of that dependency are measured in lives.

VAi’s early work was immediate and practical. The organisation mobilised public and private capability to strengthen Uganda’s vaccination systems from the inside out — expanding outreach to underserved communities, reinforcing cold-chain infrastructure, and building the administrative and logistical scaffolding that safe vaccine delivery demands. It was unglamorous, essential work, and it established something that no amount of imported expertise could substitute: a deep, working knowledge of what Ugandan health infrastructure actually needs.

That foundation is now being put to its larger purpose. Today, VAi is executing one of the most consequential transitions in Uganda’s health sector — shifting from vaccine access facilitation to full biopharmaceutical manufacturing capability. At a GMP-aligned production platform under development in Ntinda, Kampala, VAi is advancing the capacity to manufacture vaccines, stem cell–based therapies, and peptide therapeutics on Ugandan soil. The significance of this move extends far beyond the factory floor. Every vaccine produced locally represents a reduction in foreign exchange exposure, a step away from supply-chain vulnerability, and a signal to the region that African institutions can build globally credible health infrastructure without waiting on external permission to begin.

What makes VAi's approach distinctive is its refusal to cut corners in the name of speed.

Quality systems, workforce readiness, and regulatory alignment are being developed in concert — not sequentially — because the organisation understands that durable manufacturing is built on standards, not shortcuts. VAi is engaging regulators and national stakeholders at every stage of development, ensuring that what emerges from Ntinda is not simply operational, but internationally credible and domestically trusted.
The roadmap from here is clear and deliberate. Full-scale, GMP-compliant manufacturing for Uganda is the immediate horizon. Regional market expansion follows as capabilities mature and quality benchmarks are consistently met. Running through every stage of that journey is a commitment to technology transfer, workforce development, and locally driven research and development — because VAi’s ambition is not to manufacture for a season, but to build a platform of expertise that remains in Uganda, grows across the continent, and reduces Africa’s long-term dependence on health technologies produced elsewhere.
The outcomes VAi is working toward are not abstract. They are measurable: stronger national health-system resilience, the creation of skilled scientific and technical jobs, reduced supply-chain vulnerability, and a biopharmaceutical platform that positions Uganda as a contributor to — not merely a consumer of — global health solutions. In an era when institutions like Africa CDC are deepening continental frameworks for disease surveillance and health workforce development, and when the global health community is increasingly aligned on the principle that African health security requires African solutions, VAi is not waiting for consensus to catch up with its work. It is already building.

For Microhaem Scientifics, VAi represents the clearest expression of a long-held belief: that the private sector has not just a role, but a responsibility, in shaping the health systems that communities depend on. VAi is that responsibility made operational — a subsidiary with a mandate, a strategy, and the institutional partnerships to see it through.

Scroll to Top